Literature DB >> 27581702

Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients.

M Simrén1,2, O S Palsson2, S Heymen2, A Bajor1,3, H Törnblom1, W E Whitehead2.   

Abstract

BACKGROUND: Fecal incontinence (FI) is a prevalent but poorly recognized problem in the general population with profound negative effects on daily life. The prevalence of FI in irritable bowel syndrome (IBS) and its association with clinical, demographic, and pathophysiological factors remain largely unknown.
METHODS: One US (n=304) and one Swedish (n=168) patient cohort fulfilling Rome III criteria for IBS completed Rome III diagnostic questions on FI and IBS symptoms, and questionnaires on IBS symptom severity, quality of life, anxiety and depression, and work productivity impairment. The patients also underwent assessments of colorectal sensitivity and motility. KEY
RESULTS: Fecal incontinence ≥ one day per month was reported by 19.7% (USA) and 13.7% (Sweden) of IBS patients. These proportions rose to 43.4% and 29.8% if patients with less frequent FI were included. Fecal incontinence prevalence was higher in older age groups, with a clear increase above age 40. Irritable bowel syndrome patients with FI reported greater overall IBS symptom severity, more frequent and loose stools, and greater urgency. Negative effects of FI on quality of life, psychological distress, and work productivity were demonstrated. No associations were found between colorectal physiology and FI. CONCLUSIONS & INFERENCES: Fecal incontinence is common in IBS patients, and similar to previous general population reports, the major risk factors for FI in IBS are older age, rectal urgency, and loose, frequent stools. When IBS patients have comorbid FI, the impact on quality of life, psychological symptoms, and work impairment appears greater.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  fecal incontinence; functional GI disorders; irritable bowel syndrome

Mesh:

Year:  2016        PMID: 27581702      PMCID: PMC5276715          DOI: 10.1111/nmo.12919

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  50 in total

1.  Prevalence and burden of fecal incontinence: a population-based study in women.

Authors:  Adil E Bharucha; Alan R Zinsmeister; G Richard Locke; Barbara M Seide; Kimberly McKeon; Cathy D Schleck; L Joseph Melton
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

2.  Risk factors for fecal incontinence: a population-based study in women.

Authors:  Adil E Bharucha; Alan R Zinsmeister; G Richard Locke; Barbara M Seide; Kimberly McKeon; Cathy D Schleck; L Joseph Melton
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

3.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

4.  Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization.

Authors:  Gena C Dunivan; Steve Heymen; Olafur S Palsson; Michael von Korff; Marsha J Turner; Jennifer L Melville; William E Whitehead
Journal:  Am J Obstet Gynecol       Date:  2010-03-12       Impact factor: 8.661

5.  Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Authors:  D L Patrick; D A Drossman; I O Frederick; J DiCesare; K L Puder
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

6.  Urgency and fecal soiling in people with bowel dysfunction.

Authors:  D A Drossman; R S Sandler; C M Broom; D C McKee
Journal:  Dig Dis Sci       Date:  1986-11       Impact factor: 3.199

7.  The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS).

Authors:  M C Reilly; A Bracco; J-F Ricci; J Santoro; T Stevens
Journal:  Aliment Pharmacol Ther       Date:  2004-08-15       Impact factor: 8.171

8.  Fecal incontinence in US adults: epidemiology and risk factors.

Authors:  William E Whitehead; Lori Borrud; Patricia S Goode; Susan Meikle; Elizabeth R Mueller; Ashok Tuteja; Alison Weidner; Milena Weinstein; Wen Ye
Journal:  Gastroenterology       Date:  2009-05-04       Impact factor: 22.682

9.  The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders.

Authors:  J Vu; V Kushnir; B Cassell; C P Gyawali; G S Sayuk
Journal:  Neurogastroenterol Motil       Date:  2014-07-29       Impact factor: 3.598

10.  Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome.

Authors:  Boris Le Nevé; Rémi Brazeilles; Muriel Derrien; Julien Tap; Denis Guyonnet; Lena Ohman; Hans Törnblom; Magnus Simrén
Journal:  Clin Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 11.382

View more
  4 in total

1.  Fecal urgency is common in constipated patients and is associated with anxiety.

Authors:  Prashant Singh; Eve Takazawa; Vikram Rangan; Sarah Ballou; Jesse Katon; Courtney McMahon; Ha-Neul Lee; Johanna Iturrino; Judy Nee; Anthony Lembo
Journal:  Neurogastroenterol Motil       Date:  2019-02-03       Impact factor: 3.598

2.  Faecal incontinence is not rare in irritable bowel syndrome.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Frontline Gastroenterol       Date:  2020-05-15

3.  Risk Factors for Fecal Urgency Among Individuals With and Without Diarrhea, Based on Data From the National Health and Nutrition Examination Survey.

Authors:  Vikram Rangan; Shuji Mitsuhashi; Prashant Singh; Sarah Ballou; William Hirsch; Thomas Sommers; Judy Nee; Johanna Iturrino; Anthony Lembo
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-21       Impact factor: 11.382

Review 4.  Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice.

Authors:  Magnus Simren; Olafur S Palsson; William E Whitehead
Journal:  Curr Gastroenterol Rep       Date:  2017-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.